Esco Cap Lunch Presentation in Zurich
12:00
Lunch presentation from EsoCap AG
EsoCap AG
(‘EsoCap’) is offering an equity investment of CHF 10 million in a private
placement at a price of CHF 28 per share, representing a pre-money valuation of
CHF 77.5 million.
The funds
from this offering will be used for the roll-out of the international patent
portfolio, preparation of the pivotal Phase III clinical trial, interactions
with regulatory authorities in the US and Europe, industrial scale-up and
production of clinical trial material for the Phase III clinical trial.
EsoCap is in
the process of preparing a commercial transaction with a major pharmaceutical
company specialising in gastroenterology and cancer. Based on state-of-the-art
valuation models, a return on investment of 3x is expected within the next two
years. This estimate is subject to market conditions, negotiations and the
successful completion of the trade sale.
About EsoCap
EsoCap AG is a
privately funded joint stock company based in Basel, Switzerland.
EsoCap has
successfully developed a unique, highly sophisticated platform technology with
multiple applications for local drug therapy in patients with severe
oesophageal diseases.
EsoCaps technology
guarantees a significantly longer contact time of drugs (small molecules,
peptides, biologics and encapsulated mRNA treatment principles) in the
oesophagus, resulting in a safe and highly effective treatment outcome.
The lead candidate
ESO-101 has received Orphan Drug Designation from the US Food & Drug
Administration (FDA) for the treatment of eosinophilic oesophagitis (EoE).
EsoCap recently successfully completed the double-blind, randomised,
placebo-controlled Phase II ACESO study with ESO-101 in five countries,
demonstrating the clinical applicability of the platform technology.
EsoCap has a strong
and diversified intellectual property position as well as a highly
complementary team and development infrastructure.
For more information,
please visit www.esocapbiotech.com and follow EsoCap on LinkedIn and Twitter.
Contact:
Isabelle Racamier
CEO
isabelle.racamier@esocapbiotech.com
Phone: +43 699 149 50
300
Speaker
12:00
Lunch presentation from EsoCap AG
- Currently, there is no globally approved medication that can be administered topically in the esophagus.
- The new application technology will be beneficial for over 370 million patients in at least 6 major indications.
- The transit time from the mouth to the stomach is ultra-short, preventing effective local treatment.
Speaker
CEO at EsoCap AG
